Whitehawk CEO granted 193,957 options, RSUs

Whitehawk Therapeutics’ CEO received option and RSU grants, and the amendment corrects the RSU vesting schedule to a one-year cliff vesting structure.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. (WHWK) reported that its chief executive officer, David James Lennon, received a stock option grant for 193,957 shares of common stock at an exercise price of $4.09 per share and a separate grant of 193,957 restricted stock units on September 15, 2026. The option vests 25% on the one-year anniversary of the September 15, 2026 vesting commencement date, with the remainder vesting in equal monthly installments over the following three years, and expires on September 15, 2036. The RSU award is structured so that 100% of the shares vest on the one-year anniversary of the same vesting commencement date, and this amendment corrects an earlier report that had shown an incorrect vesting schedule.

Insider Trade Summary

Grant/Award: 387,914 shares

Grant/Award 2 txns

Insider Lennon David James

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	193,957	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	193,957	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 193,957 contracts (Direct); Restricted Stock Units — 193,957 contracts (Direct)

Footnotes (3)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
3. F3. The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

Key Figures

Stock options granted: 193,957 shares Option exercise price: $4.09 per share RSUs granted: 193,957 units +3 more

6 metrics

Stock options granted 193,957 shares Stock option grant to CEO on September 15, 2026

Option exercise price $4.09 per share Exercise price for CEO stock option grant

RSUs granted 193,957 units Restricted Stock Unit grant to CEO on September 15, 2026

Option expiration date September 15, 2036 Expiration of CEO stock option grant

Vesting Commencement Date September 15, 2026 Start date for both option and RSU vesting schedules

RSU vesting 100% after 1 year All RSU shares vest on the one-year anniversary of the Vesting Commencement Date

Key Terms

Restricted Stock Units, Vesting Commencement Date, Equity Incentive Plan, Service Provider

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean September 15, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did WHWK grant to its CEO on September 15, 2026?

Whitehawk Therapeutics granted CEO David James Lennon a stock option for 193,957 shares of common stock at $4.09 per share and a separate grant of 193,957 restricted stock units, each RSU representing a right to receive one WHWK common share.

How do the new stock options for the WHWK CEO vest?

The CEO’s stock option vests with 25% of the shares vesting on the one-year anniversary of the September 15, 2026 vesting commencement date, and 1/48th of the total shares vesting monthly thereafter so that all shares are fully vested by the four-year anniversary.

What is the vesting schedule for the WHWK CEO’s RSU grant?

Subject to continued service, 100% of the 193,957 RSUs vest on the one-year anniversary of the September 15, 2026 vesting commencement date. This amendment specifically corrects the vesting schedule that had been reported incorrectly in an earlier report.

What is the exercise price and expiration date of the WHWK CEO’s stock options?

The stock option granted to the CEO covers 193,957 shares of Whitehawk common stock at an exercise price of $4.09 per share and has an expiration date of September 15, 2036, subject to the CEO continuing as a service provider through the applicable vesting dates.

Does the WHWK CEO’s RSU grant deliver shares on a one-for-one basis?

Yes. Each restricted stock unit represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. common stock upon vesting, so the 193,957 RSUs correspond to a potential issuance of 193,957 common shares.

Were the WHWK CEO’s transactions made under a Rule 10b5-1 trading plan?

No. The report indicates that the Rule 10b5-1 trading plan checkbox is not selected, and there is no footnote indicating that these equity grants were made pursuant to any Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:42 PM Accepted by SEC EDGAR 09/18/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lennon David James

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/15/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.09	09/15/2026		A		193,957		(1)	09/15/2036	Common Stock	193,957	$0	193,957	D
Restricted Stock Units	(2)	09/15/2026		A		193,957		(3)	(3)	Common Stock	193,957	$0	193,957	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

3. The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)